Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
As the first quarter of 2026 draws to a close, the global mergers and acquisitions (M&A) market has delivered a paradox that is reshaping the financial landscape. Preliminary data reveals that total deal values surged to a record-breaking $813.3 billion in Q1, a staggering leap that signals a
In a decisive show of confidence for the biotechnology sector, institutional heavyweights have significantly ramped up their positions in Amgen (NASDAQ: AMGN) throughout the first quarter of 2026. Regulatory filings and recent market data indicate a coordinated accumulation by major asset managers, who are increasingly viewing the California-based biotech giant
As of March 23, 2026, the American corporate engine has proven itself to be remarkably high-revving, even as the global landscape shifts beneath it. Despite a volatile start to the year characterized by a spike in energy prices and the implementation of sweeping new fiscal policies, the S&P 500
As the first quarter of 2026 comes to a close, the financial world is buzzing with a renewed sense of optimism. Goldman Sachs (NYSE: GS) has released its highly anticipated 2026 Global M&A Outlook, titled "Think Big, Build Bigger," predicting a massive 15% increase in merger and acquisition deal
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have...
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl...
The promise of a mid-March market recovery vanished this week as a short-lived "relief rally" gave way to a wave of "buyer’s remorse," leaving investors scrambling for cover. What began on Monday as a hopeful bounce driven by artificial intelligence optimism and a temporary dip in energy costs ended
